{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:08:45Z","timestamp":1791065325554,"version":"4.1.0"},"reference-count":57,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>\n                    CFZ533 (iscalimab) is a nondepleting anti-CD40 antibody intended for inhibition of transplant organ rejection and treatment of autoimmune diseases. In a safety assessment in rhesus monkeys, CFZ533 was administered for 13 weeks up to 150 mg\/kg\/week subcutaneously. CFZ533 was shown previously to completely inhibit primary and secondary T-cell-dependent antibody responses. CD40 is expressed on B cells, antigen-presenting cells, and endothelial and epithelial cells, but is not expressed on T cells. Here, we demonstrate the complete suppression of germinal center formation in lymphoid organs. CFZ533 was well tolerated and did not cause any dose-limiting toxicity. However, the histological evaluation revealed increased numbers of CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in the T-cell-rich areas of lymph nodes enlarged in response to observed adenovirus and Cryptosporidium infections which suggest that T-cell immune function was unaffected. Background infections appear as the condition leading to unraveling the differential immunosuppressive effects by CFZ533. The presence of T cells at lymph nodes draining sites of infections corroborates the immunosuppressive mechanism, which is different from calcineurin-inhibiting drugs. Furthermore, CFZ533 did not show any hematological or microscopic evidence of thromboembolic events in rhesus monkeys, which were previously shown to respond with thromboembolism to treatment with anti-CD154 antibodies.\n                  <\/jats:p>","DOI":"10.1177\/01926233221100168","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T03:16:27Z","timestamp":1655867787000},"page":"712-724","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study"],"prefix":"10.1177","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3038-4802","authenticated-orcid":false,"given":"Thierry D.","family":"Flandre","sequence":"first","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-270X","authenticated-orcid":false,"given":"Keith G.","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal J.","family":"Espi\u00e9","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"},{"name":"Roche, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Rubic-Schneider","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"bibr1-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13377"},{"key":"bibr2-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14872"},{"key":"bibr3-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfy196"},{"key":"bibr4-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1002\/biof.62"},{"key":"bibr5-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.06.002"},{"key":"bibr6-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00932.x"},{"key":"bibr7-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(95)90135-3"},{"key":"bibr8-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.63.3.373"},{"key":"bibr9-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(03)00024-8"},{"key":"bibr10-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.67.1.2"},{"key":"bibr11-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-70630-6_11"},{"key":"bibr12-01926233221100168","doi-asserted-by":"publisher","DOI":"10.2174\/157339509789503989"},{"key":"bibr13-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.1.157"},{"key":"bibr14-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104533"},{"key":"bibr15-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000116392.72152.75"},{"key":"bibr16-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1038\/72162"},{"key":"bibr17-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0757-4"},{"key":"bibr18-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000116563.72763.83"},{"key":"bibr19-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200210150-00006"},{"issue":"11","key":"bibr20-01926233221100168","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.4049\/jimmunol.157.11.4963","volume":"157","author":"Lund J","year":"1996","journal-title":"J Immunol"},{"key":"bibr21-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1080\/01926230600939997"},{"key":"bibr22-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1177\/019262330002800317"},{"key":"bibr23-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/01.Tp.0000116563.72763.83"},{"key":"bibr24-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00960-07"},{"key":"bibr25-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.39.4.1580-1585.2001"},{"key":"bibr26-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000100046.06009.b0"},{"key":"bibr27-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.49.2.191"},{"key":"bibr28-01926233221100168","first-page":"197","volume-title":"Nonhuman Primates in Biomedical Research","volume":"2012","author":"Strait K","edition":"2"},{"key":"bibr29-01926233221100168","doi-asserted-by":"publisher","DOI":"10.3109\/15476910903213521"},{"key":"bibr30-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205150-00012"},{"issue":"1","key":"bibr31-01926233221100168","first-page":"57","volume":"58","author":"Carville A","year":"2008","journal-title":"Comp Med"},{"key":"bibr32-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.20.12681-12691.2005"},{"key":"bibr33-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2005020202"},{"key":"bibr34-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175034"},{"key":"bibr35-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143305"},{"key":"bibr36-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646420"},{"key":"bibr37-01926233221100168","unstructured":"US Food & Drug Administration. Pimecrolimus (Elidel). Published 2001. Accessed October 4, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21-302_Elidel.cfm."},{"key":"bibr38-01926233221100168","unstructured":"US Food & Drug Administration. Tacrolimus (Prograf). Published 1994. Accessed October 4, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/050708_prograf_toc.cfm."},{"key":"bibr39-01926233221100168","unstructured":"European Medicines Agency. Tacrolimus (Advagraf). Published 2007. Accessed October 4, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/advagraf-epar-scientific-discussion_en.pdf."},{"key":"bibr40-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0012.1999.130301.x"},{"key":"bibr41-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-199707000-00032"},{"key":"bibr42-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/39.11.2219"},{"key":"bibr43-01926233221100168","unstructured":"US Food & Drug Administration. Sirolimus (Rapamune). Published 1999. Accessed October 4, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21083A.cfm."},{"key":"bibr44-01926233221100168","unstructured":"European Medicines Agency. Sirolimus (Rapamune)\u2014EPAR\u2014scientific discussion. Published 2006. Accessed October 4, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/rapamune-epar-scientific-discussion_en.pdf."},{"key":"bibr45-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00810-9"},{"key":"bibr46-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2003.12.069"},{"key":"bibr47-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2003.12.027"},{"key":"bibr48-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(00)00568-4"},{"key":"bibr49-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000110291.29370.C0"},{"key":"bibr50-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1002\/art.29009"},{"key":"bibr51-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1002\/art.10856"},{"key":"bibr52-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02526.x"},{"key":"bibr53-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12082"},{"key":"bibr54-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12630"},{"key":"bibr55-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09251.x"},{"key":"bibr56-01926233221100168","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.681655"},{"key":"bibr57-01926233221100168","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-201407151-00353"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233221100168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/01926233221100168","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233221100168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:42:44Z","timestamp":1777653764000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/01926233221100168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1177\/01926233221100168"],"URL":"https:\/\/doi.org\/10.1177\/01926233221100168","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}